Biodrugs

Papers
(The H4-Index of Biodrugs is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond371
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis337
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy140
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor116
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis101
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery100
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome81
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making78
Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials68
Why Product Drift Is Not an Issue for Biosimilars/Biologics: Start the Same, Stay the Same63
Acknowledgement to Referees56
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials47
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart44
CAR-T Cells and the Kidney: Insights from the WHO Safety Database43
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202240
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?39
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells38
Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France38
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study36
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis36
Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities35
Progress and Challenges in the Treatment of Fabry Disease34
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase34
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review34
Malaria Vaccines: Progress to Date32
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer31
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?30
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects29
Interleukin-23 Inhibitors in Inflammatory Bowel Disease29
0.075515031814575